EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Triggering global regulatory submissions this year for the treatment of obesity
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
The company is bringing precision therapies for gynaecological cancers
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Subscribe To Our Newsletter & Stay Updated
